摘要
目的探讨脑立清胶囊联合吲达帕胺治疗高血压合并冠心病的临床效果。方法选取2020年5月至2022年2月收治的82例高血压合并冠心病患者为研究对象,按照随机数字表法将其分为对照组与观察组,各41例。对照组在常规治疗基础上增加吲达帕胺片治疗,观察组在对照组基础上增加脑立清胶囊治疗。比较两组的治疗效果。结果观察组的治疗总有效率明显高于对照组(P<0.05)。治疗后,观察组的内皮素(ET)、血管活性肽(Salusin-β)、N-末端脑钠肽前体(NT-proBNP)水平低于对照组,一氧化氮(NO)水平高于对照组(P<0.05)。治疗后,观察组的过氧化物酶体增殖物激活受体-γ(PPAR-γ)、单核细胞趋化蛋白-1(MCP-1)、非对称性二甲基精氨酸(ADMA)水平显著低于对照组(P<0.05)。结论脑立清胶囊联合吲达帕胺治疗高血压合并冠心病的效果满意,可改善血管内皮功能,降低患者的心脏负荷,调节PPAR-γ、MCP-1、ADMA表达,值得推广。
Objective To explore the clinical effect of Naoliqing capsule combined with indapamide in the treatment of hypertension complicated with coronary heart disease.Methods A total of 82 patients with hypertension complicated with coronary heart disease admitted from May 2020 to February 2022 were selected as the research objects and divided into control group and observation group according to the random number table method,with 41 cases in each group.The control group was treated with indapamide tablets on the basis of routine treatment,and the observation group was treated with Naoliqing capsule on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the levels of endothelin(ET),vasoactive peptide(Salusin-β)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in the observation group were lower than those in the control group,and the level of nitric oxide(NO)was higher than that in the control group(P<0.05).After treatment,the levels of peroxisome proliferator-activated receptor-γ(PPAR-γ),monocyte chemotactic protein-1(MCP-1)and asymmetric dimethylarginine(ADMA)in the observation group were significantly lower than those in the control group(P<0.05).Conclusion The Naoliqing capsule combined with indapamide in the treatment of hypertension complicated with coronary heart disease has satisfactory effect,it can improve vascular endothelial function,reduce cardiac load of patients,and regulate the expression of PPAR-γ,MCP-1 and ADMA,which is worth promoting.
作者
庄惊奇
徐颖
祁超静
李光
徐春华
ZHUANG Jingqi;XU Ying;QI Chaojing;LI Guang;XU Chunhua(Lintong Rehabilitation and Recuperation Center,Xi'an 710061;Xi'an Central Hospital,Xi'an 710003,China)
出处
《临床医学研究与实践》
2023年第32期124-127,共4页
Clinical Research and Practice
关键词
脑立清胶囊
吲达帕胺
高血压
冠心病
Naoliqing capsule
indapamide
hypertension
coronary heart disease
